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Abstract: Cannabinoids have been proposed to possess neuroprotective properties; though their mechanism of action 
remains contentious, they are posited to prevent neurodegenerative disorders, including Parkinson’s disease, the pathogenesis 
of which has not been established. Recent studies have demonstrated that induction of proteasomal dysfunction in animal 
models results in a phenotype similar to Parkinson’s disease. Here, we investigated the neuroprotective function of a synthetic 
cannabinoid-receptor agonist (WIN55.212.2) in dopaminergic neuronal death induced by a proteasomal synthase inhibitor 
(PSI), additionally testing the hypothesis that WIN55.212.2 modulates cytoplasmic accumulation of parkin and α-synuclein, 
a key feature of proteasomal dysfunction in Parkinson’s. WIN55.212.2 protects PC12 cells from PSI-induced cytotoxicity, 
concomitantly inhibiting PSI-induced polyADP ribose polymerase expression and activation of caspase-3. While PSI induces 
cytoplasmic accumulation of α-synuclein and parkin, WIN55.212.2 counters these eff  ects. Interestingly, however, while PSI 
induces the activation and nuclear translocalization of nuclear factor κB, WIN55.212.2 potentiates this eff  ect. Th   ese data are 
suggestive that WIN55.212.2 might confer a neuroprotective benefi  t in PSI-induced proteasomal dysfunction, and could further 
protect against neuronal degeneration stemming from cytoplasmic accumulation of α-synuclein and parkin. These results 
indicate that WIN55.212.2 may be a candidate for treatment of neurodegenerative diseases, including Parkinson’s disease.
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are mediated by activation of their cognate receptors on 
presynaptic nerve ends [2]. Various types of cannabinoid 
receptors, including the orphan G-protein coupled receptors 
CB1 and CB2, are found in blood vessels, the central nervous 
system, and immune cells [3-5]. While CB1 is expressed 
abundantly in several areas in the brain as well as in 
peripheral tissues, CB2 is primarily expressed in the immune 
system [6, 7], although it was recently detected at low levels 
in peripheral nerve endings, microglial cells, and astrocytes, 
as well as in the cerebellum and brain stem [8]. CB1 receptor 
activation is involved in the control of neural cell fate [9] and 
mediates neuroprotectivity in diff  erent in vivo models of brain 
injury, including excitotoxicity and ischemia [10, 11].
Introduction
Cannabinoids (CBs) from the Cannabis sativa L. plant, 
including tetrahydrocannabinol, the principal psychoactive 
component of marijuana, produce euphoria and relaxation 
and also impair motor coordination, perception of time, 
and short-term memory [1]. The principal actions of CBs Anat Cell Biol 2011;44:135-142 Posung Jeon, et al 136
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In recent years, the capacity of CBs to effect neuro  pro-
tec  tion and neurotoxicity has received increasing attention. 
Evidence of possible neuroprotective eff  ects has accumulated 
in vitro from models of neurodegenerative diseases, including 
Alzheimer’s and Parkinson’s diseases and multiple sclerosis, 
as well as from in vivo clinical trial data [12-14]. These 
compounds are also able to decrease infl  ammation by acting 
on glial cells that influence neuronal survival [12]. The 
molecular mechanisms underlying cannabinoid-mediated 
neuroprotection are still poorly understood, but may include 
the direct activation of neuronal survival signaling pathways 
through cannabinoid receptors [15] or indirect effects 
mediated by microglial CB2-receptor stimulation [16]. 
The ubiquitin-proteasome system (UPS) is the primary 
pathway effecting degradation of unwanted intracellular 
soluble proteins, including those that are mutant, misfolded, 
damaged, or mislocalized, and can operate in the cytoplasm, 
nucleus, and secretory system of eukaryotic cells [17, 18]. 
Ubiquitin-conjugated target proteins are routed to the 
proteasome, a 2,000 kDa ATP-dependent proteolytic complex, 
for degradation [18, 19]. Failure of ubiquitylation results in 
protein accumulation and cell death [20, 21]. Recent studies 
have demonstrated that ubiquitylation-mediated degradation 
or modulation of protein activity is a common regulatory 
mechanism in apoptosis [22, 23]. 
An increasing body of evidence suggests that UPS 
dysfunction may play an important role in the pathogenesis 
of neurodegenerative diseases, especially Parkinson’s disease. 
Indeed, synthetic proteasomal inhibitors induce dopaminergic 
neuronal cell death and the appearance of cytoplasmic Lewy-
body like eosinophilic inclusions, two primary features of 
Parkinson’s [24]. However, there is currently no proof that 
CBs aff  ect proteasomal degradation. Nuclear factor κB (NF-
κB), a key transcription factor that regulates many genes 
involved in infl  ammatory processes, cell diff  erentiation, and 
cell death [25], can also be induced by proteasomal inhibition. 
Interestingly, treatment with the CB1-receptor agonist 
WIN55.212.2 is associated with inhibition of NF-κB activity 
and cell death [26]. 
In this report, we demonstrate that WIN55.212.2 inhibits 
PC12 dopaminergic neuronal cell apoptosis by proteasomal 
inhibition as well as NF-κB activation. In addition, we show 
that it can prevent neuronal accumulation of α-synuclein and 
parkin. We further discuss the importance of these fi  ndings 
with regard to regulation of the UPS and neuronal response 
to CBs. 
Materials and Methods
Cell culture
PC12 dopaminergic neuronal cells were obtained from the 
Korean Cell Line Bank (KCLB, Korea) and were cultured in 
RPMI-1640 with heat-inactivated fetal bovine serum, 2 mM 
glutamine, and 100 units/ml penicillin/streptomycin (Gibco-
BRL, San Diego, CA, USA). Cells were incubated at 37
oC in 
5% CO2 under conditions of 85-95% humidity; aft  er 48 hours, 
the medium was changed and cells were exposed for 24 hours 
to proteasomal synthase inhibitor (PSI; Sigma, St. Louis, MO, 
USA) and/or a cannabinoid-receptor agonist (WIN55.212.2, 
Sigma) dissolved in dimethyl sulfoxide (DMSO). 
   
Preparation of small molecules
PSI (Z-Ile-Glu(OtBu)-Ala-Leu-al) and WIN55.212.2 were 
prepared as 1 mM or 50 mM stock solutions, respectively, in 
DMSO, and were diluted in culture medium prior to addition 
to cells. Thiazolyl Blue Tetrazolium Bromide (MTT; Sigma) 
was prepared as a 2 mg/ml stock solution in phosphate 
buff  ered saline (PBS).
     
Cell viability assays
Cell viability was determined using the MTT assay. 
Approximately 5×10
3 cells were plated in each well of a 96-
well plate and allowed to attach to the substrate for 24 hours. 
Th   e cells were then exposed to 1 μM PSI with 1, 5, or 10 μM 
WIN55.212.2 for a further 24 hours. Subsequently, 50 μl of 
MTT stock solution (see above) were added to each well and 
absorbance measured at 570 nm with a Bio-Tek microplate 
reader (Winooski, VT, USA). Reduction in cell viability was 
expressed relative to that of untreated cells.
     
Western blotting
After 24-hour exposure to 1 μM PSI with 10 μM 
WIN55.212.2, PC12 cells were resuspended in 200 μl lysis 
buffer (1.0 mM PMSF, 1.0 mM EDTA, 1 μM pepstatin A, 1 
μM leupeptin, 1 μM aprotinin) and incubated on ice for 45 
minutes. Lysates were centrifuged at 20,000 ×g for 20 minutes 
at 4
oC, and supernatant stored at −70
oC prior to sodium 
dodecyl sulfate polyacrylamide gel electrophoresis. Protein 
concentrations were determined using the Bradford assay. All 
steps of protein preparation were carried out at 4
oC. 
Supernatant aliquots containing 60 μg total protein were 
added to an equal volume of 2× sample buff  er; samples were 
boiled for 5 minutes and loaded onto 12% polyacrylamide Cannabinoid receptor agonist protects dopaminergic neuron
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gels for electrophoresis. Samples were transferred onto 
polyvinylidene difluoride membranes (Millipore, Bedford, 
MA, USA). After blocking with 5% skim milk, membranes 
were incubated with polyclonal antibodies against nuclear 
polyADP ribose polymerase (PARP), NF-κB, or caspase-3 
(all 1 : 1,000, Cell Signaling Technology, Berverly, MA, 
USA). Antibodies against α-synuclein (1 : 1,000) and 
extracellular signal regulated kinase 2 (1 : 10,000) were 
purchased from Santa Cruz Biotechnology (Santa Cruz, CA, 
USA). Protein was visualized on X-ray film using PicoWest 
Chemiluminescent Substrate (Pierce, Rockford, IL, USA). All 
experiments were performed at least in triplicate. Statistical 
analysis was performed using the Student’s t-test (P<0.05).
Immunocytochemistry
For double immunolabeling of tyrosine hydroxylase (TH), 
parkin, NF-κB, and cleaved caspase-3, PC12 cells treated with 
PSI and WIN55.212.2 were fi  xed and incubated with primary 
antibody in PBS containing 1% normal goat serum and 0.1% 
Triton X-100 at 4
oC overnight. Th   e primary antibodies used 
were mouse anti-TH (1 : 200), mouse anti-NF-κB (1 : 200), 
mouse anti-parkin (1 : 200) and rabbit anti caspase-3 (1 : 500), 
all of which were purchased from Santa Cruz Biotechnology. 
Primary antibody binding was detected with donkey CY3-
conjugated anti-rabbit IgG and donkey CY5-conjugated anti-
mouse IgG fl  uorescently labeled secondary antibodies (1 : 200, 
Jackson Immunoresearch Laboratory, West Grove, PA, USA). 
Labeled cells were imaged using a standard fluorescence 
microscope (Nikon, Tokyo, Japan) and images captured with 
a digital camera attachment. Additional fluorescent images 
were obtained via confocal microscopy (LSM META 510, 
Carl Zeiss, Jena, Germany).
Results
WIN55.212.2 protects PC12 dopaminergic neuronal 
cells from death due to proteasomal inhibition
We fi rst wished to ascertain the infl  uence of the synthetic 
cannabinoid-receptor agonist WIN55.212.2 on cell viability. 
By MTT assay, PC12-cell viability was reduced signifi  cantly by 
exposure to PSI, but this eff  ect was reversed by WIN55.212.2 
(Fig. 1). Th   ese results demonstrate that WIN55.212.2 inhibits 
cell death in PC12 cells by counteracting the activity of a 
proteasomal inhibitor. 
WIN55.212.2 blocks the caspase-3 activation induced 
by PSI treatment of PC12 cells
To elucidate the mechanism of this WIN55.212.2-mediated 
PC12-cell survival, we assessed activation of the apoptotic 
eff  ector protein caspase-3. Western-blotting analyses revealed 
that PSI treatment in the absence of WIN55.212.2 increased 
levels of cleaved caspase-3, but this effect was reversed by 
co-administration of the compounds. We also performed 
immunofluorescent staining of PC12 cells (Fig. 2), which 
likewise revealed that expression of cleaved caspase-3 
increased with PSI addition but decreased with WIN55.212.2 
and PSI co-administration. These data suggest that 
WIN55.212.2 inhibits PC12-cell apoptosis via modulation 
of caspase-3 activation and by promotion of cellular survival 
behavior.
     
WIN55.212.2 suppresses PSI-induced expression of 
α-synuclein and parkin 
As inhibition of the proteasome elicits an increase in 
cellular levels of ubiquitylated proteins, as well as inducing the 
appearance of parkin- and α-synuclein positive perinuclear 
structures, we asked if proteasomal dysfunction could also 
lead to the formation of discrete cytoplasmic inclusions in 
dopaminergic PC12 cells, and if WIN55.212.2 could reduce 
the numbers of parkin- and α-synuclein-positive structures 
(Fig. 3). We examined the existence of α-synuclein and 
parkin-positive structures in PC12 cells incubated with PSI 
by immunofluorescence. While α-synuclein and parkin 
Fig. 1. MTT assay. Administration of proteasomal synthase inhi-
bitor (PSI) induces PC12-cellular death. Co-administration of 
WIN55.212.2 protects PC12 cells from cell death. Note that there 
are statically significant decreases (*) in cytotoxicity in cells co-
administered PSI and WIN55.212.2 (P<0.05; data represent mean and 
standard deviation).Anat Cell Biol 2011;44:135-142 Posung Jeon, et al 138
www.acbjournal.org doi: 10.5115/acb.2011.44.2.135
from cultured PC12 cells and assayed protein expression in 
each fraction. By Western blotting, we found that the level 
of NF-κB expression in cytoplasmic lysates did not change 
with the addition of PSI and WIN55.212.2. In contrast, that 
in nuclear lysates increased with the addition of PSI, and co-
administration of WIN55.212.2 with PSI potentiated this 
effect. These results suggest that WIN55.212.2 modulates 
apoptosis induced by proteasomal inhibition, in part through 
its regulation of NF-κB activity. 
Discussion
Th   e primary manifestation of Parkinson’s disease pathology 
is degeneration of dopaminergic neurons in the substantia 
nigra pars compacta, coupled with the appearance of 
cytoplasmic inclusions known as Lewy bodies. Together, these 
result in loss of the nigrostriatal pathway and a reduction 
levels were augmented following the addition of PSI, co-
administration of WIN55.212.2 and PSI resulted in a 
significant reduction in expression of either protein. These 
results suggest that proteasomal function is modulated by the 
addition of WIN55.212.2.
     
WIN55.212.2 modulates the NF-κB signaling pathway 
following treatment with PSI 
NF-κB is an apoptotic effector operating independent of 
the mitochondrial apoptosis pathway. To evaluate the eff  ect of 
proteasomal dysfunction on NF-κB’s proapoptotic activities, 
we performed Western blots to detect its expression in PC12-
cell lysates in the presence of PSI and WIN55.212.2. NF-κB 
expression was enhanced by addition of PSI; interestingly, this 
increase was potentiated through co-administration of PSI 
and WIN55.212.2 (Fig. 4). 
NF-κB is activated by nuclear translocation. To study this 
activation, we separately isolated the cytoplasm and nucleus 
Fig. 2. WIN55.212.2 inhibits pro-
teasomal synthase inhibitor (PSI)-
induced activation of caspase-3. (A) 
Representative immunofluorescent 
micrographs of PC12 cells cultured in 
the presence of PSI and WIN55.212.2 
and stained for activated caspase-3. 
Note the decreased staining in cultures 
where PSI and WIN55.212.2 were 
co-administered, while staining was 
increased in cultures treated with PSI 
alone. (B) Upper panel: representative 
Western blots for cleaved caspase-3 in 
lysates of PC12 cells cultured in the 
presence or absence of WIN55.212.2 
and PSI (normalized for expression of 
extracellular signal-regulated kinase 2 
[ERK2]). Lower panel: quantitation of 
cleaved caspase-3 expression in PC12 
cells as described above. Note that there 
are statically significant changes(*) 
in cleaved caspase-3 expression in 
cultures treated with PSI alone and 
in those treated with both PSI and 
WIN55.212.2 (P<0.05; data represent 
mean and standard deviation).Cannabinoid receptor agonist protects dopaminergic neuron
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Fig. 3. WIN55.212.2 inhibits the proteasomal synthase inhibitor (PSI)-induced accumulation of α-synuclein and parkin. (A) Representative 
immunofl  uorescent micrographs of PC12 cells cultured in the presence of PSI and WIN55.212.2 and stained for  α-synuclein and parkin (arrows). 
Note the decreased staining in cultures treated with both PSI and WIN55.212.2 relative to that in cultures treated with PSI alone. (B) Upper panel: 
representative Western blots for α-synuclein and parkin in lysates of PC12 cells cultured in the presence or absence of WIN55.212.2 and PSI. 
Lower panel: quantitation of α-synuclein and parkin expression in PC12 cells as described above (arrows). Note that there are statically signifi  cant 
changes in α-synuclein and parkin expression in cultures treated with PSI alone compared to those treated with both PSI and WIN55.212.2 (P<0.05; 
data represent mean and standard deviation). ERK2, extracellular signal-regulated kinase 2.Anat Cell Biol 2011;44:135-142 Posung Jeon, et al 140
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of dopamine levels in the striatum [27]. The mechanism 
responsible for neurodegeneration in Parkinson’s disease has 
not been conclusively demonstrated, although there is some 
evidence of apoptotic cytotoxicity initiated concomitant with 
a cascade of events including oxidative stress, mitochondrial 
dysfunction, infl  ammation, and excitotoxicity [28].
Recent studies have suggested that a defect in the UPS 
plays a major role in the pathogenesis of some hereditary 
and sporadic forms of Parkinson’s disease [24, 29]. Patients 
with sporadic Parkinson’s disease were observed to exhibit 
a significant reduction in levels of α-subunits of the 20S 
proteasome, along with a diminution in the compensatory 
activities of the PA700 and PA28 proteasomal activators. 
Inhibition of proteasomal function in cultured cells can 
also lead to selective dopaminergic cell degeneration in 
conjunction with formation of inclusion bodies [30]. 
Synthetic proteasomal inhibitors may likewise cause 
UPS dysfunction, recapitulating features of Parkinson’s. PSI 
induces dopaminergic neuronal-cell death and the emergence 
of cytoplasmic Lewy-body like eosinophilic inclusions 
containing α-synuclein and parkin [24]. Additionally, 
the administration of PSI induces the expression and 
accumulation of α-synuclein and parkin in primary cultured 
neurons. These results indicate that proteasomal inhibitors 
play at least a partial role in neurodegeneration in the mouse 
model for Parkinson’s disease [31]. 
In the present study, PSI treatment resulted in increased 
expression of α-synuclein in PC12-cell lysates. Interestingly, 
we found that the CB receptor agonist WIN55.212.2 could 
modulate the UPS in this cell-type. Moreover, WIN55.212.2 
altered neuronal accumulation of α-synuclein, a Lewy-body 
component in Parkinson’s disease. While pharmacological 
proteasomal inhibition increases PC12-cell death, 
administration of WIN55.212.2 confers a protective effect. 
To determine the signaling pathway responsible for this 
neuroprotection, we used Western blotting to assess activation 
of caspase-3 in response to co-administration of WIN55.212.2 
and PSI. We found that PSI triggered the apoptotic pathway 
through caspase-3 activation, but that WIN55.212.2 rather 
inhibited this activation. 
The data are still controversial concerning the effects of 
CBs on neural cell survival. CBs have been demonstrated 
to induce apoptosis in several neural or neuronal cell lines, 
as well as in primary neurons [10, 32]; at the same time, 
however, numerous reports are indicative of neuroprotective 
properties of CBs through inhibition of apoptosis and 
necrosis in vitro and in vivo [26, 33-35]. 
A cannabinoid-receptor 2 ligand can protect against 
apoptosis effected through the mitochondrial pathway in 
an auditory cell line, blocking the activation of a series of 
caspases, including caspase-3, as well as cleavage of PARP 
and cytochrome c release [36]. In another report, however, 
the synthetic cannabinoid delta(9)-tetrahydrocannabinol 
induced apoptosis in vitro in neonatal rat brain cultures 
via CB receptor 1. A synthetic cannabinoid has also been 
demonstrated to activate the stress-activated protein kinase 
c-jun N-terminal kinase, as well as the pro-apoptotic protease 
caspase-3. In a separate study of cultured cortical neurons, 
tetrahydrocannabinol activated caspase-3 [37], and CB1 
receptor activation was also found to exert a neuroprotective 
effect in different in vivo models of brain injury including 
ischemia [11, 38]. However, in vivo administration of delta(9)-
tetrahydrocannabinol in adult rats was not associated with 
apoptotic pathway induction in the cerebral cortex. 
Fig. 4. WIN55.212.2 increases intranuclear expression of nuclear 
factor κB (NF-κB). Upper panel: representative Western blots for 
NF-κB in nuclear lysates of PC12 cells cultured in the presence or 
absence of WIN55.212.2 and proteasomal synthase inhibitor (PSI). 
Lower panel: quantitation of nuclear NF-κB expression in PC12 cells 
as described above. Note that there are statistically signifi  cant changes 
in intranuclear NF-κB expression in cultures treated with PSI alone 
compared to those treated with both PSI and WIN55.212.2 (P<0.05; 
data represent mean and standard deviation). ERK2, extracellular 
signal-regulated kinase 2.Cannabinoid receptor agonist protects dopaminergic neuron
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To determine the degree of PC12-cell apoptosis after 
administration of PSI and WIN55.212.2, we assessed cell 
viability and levels of activated PARP and caspase-3. We 
found that administration of WIN55.212.2 improved cellular 
survival via caspase-3 inactivation. Importantly, however, 
the duration of WIN55.212.2 exposure is a determinant of 
toxicity. Whereas in previous reports cells were treated only 
briefly with the compound, for periods ranging from 30 
minutes to 2 hours, in our study, PC12 cells were exposed 
to PSI and WIN55.212.2 for two days, and thus our results 
indicate that prolonged exposure may be protective. 
Recently, CBs have been identified as therapeutic 
candidates for amelioration of Parkinson’s disease symptoms. 
WIN55.212.2 may attenuate the action of dopaminergic 
drugs and modulate release of neurotransmitters in the 
striatum, with consequent improvement of motor function in 
Parkinson’s patients [39]. However, the results of the present 
study suggest that WIN55.212.2’s therapeutic importance 
may lie in directly blocking dopaminergic neuronal death and 
α-synuclein accumulation. 
The transcription factor NF-κB regulates numerous 
biological functions; the mechanisms that ensure selective 
termination of its activity are not fully understood. However, 
whereas proteasomal activity contributes to the shutoff of 
NF-κB dependent gene expression, proteasomal inhibition 
prevents termination of NF-κB activity, increasing expression 
of NF-κB as well as its target genes [40]. We find that PSI 
induces the expression of NF-κB subunits.             
WIN55.212.2 and other CB-receptor agonists modulate 
NF-κB dependent transcription. In general, NF-κB functions 
to counteract apoptosis. In dendritic cells, phosphorylation 
of inhibitor of κB-α and the activation and intranuclear 
localization of NF-κB are enhanced by a 30-minute exposure 
to WIN55.212.2 [26], suggesting that WIN55.212.2 may 
participate in immunoregulation through NF-κB activation. 
In other reports, 2-hour treatment with WIN55.212.2 
inhibited PC12-cell activation of NF-κB [41]. Our findings 
show that activation of NF-κB is induced by longterm 
exposure to WIN55.212.2 and PSI. WIN55.212.2 appears 
not only to modulate the mitochondrial apoptosis pathway, 
but also to protect PC12 cells from PSI-induced cell death 
through NF-κB mediated gene induction.
Given our findings that WIN55.212.2 restricts caspase 
activity in PC12 cells undergoing proteasomal inhibition, 
it is likely that WIN55.212.2 protects neurons from cell 
death due to proteasomal dysfunction. WIN55.212.2 
modulates the UPS through an unknown mechanism. Th  us, 
a more complete understanding of the complex, dynamic 
interactions between the UPS and CBs appears warranted if 
CBs are to be considered candidates as therapeutic agents for 
neurodegenerative diseases such as Parkinson’s that involve 
underlying dysfunction of the proteasomal machinery.   
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